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Sameh Mortaz Hejri1, Mehrdad Faizi2 and Mohammad Babaeian3,4*Abstract
Zolpidem is a popular drug indicated for the short-term treatment of insomnia. Side effects are not uncommon
with zolpidem. Herein we describe an Iranian 27-year-old man with no known mood disorder or
neuropsychological disease who attempted suicide upon taking zolpidem. There are two interesting facts about this
case: Firstly, the patient had not history of suicide attempt or thinking. Secondly, this case had experienced suicide
ideation after taking 20 mg of zolpidem, suggesting a possible correlation between zolpidem psychological effects
and dangerous psychological behaviors.
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Zolpidem is an Imidazopyridine agent indicated for the
short-term treatment of insomnia [1,2]. It has gained
popularity as an alternative to benzodiazepine for the
treatment of insomnia because of its milder and less
problematic side effects [3]. Nevertheless, side effects are
not uncommon with zolpidem. Hajak and Babdelow in
1998 studied 16,944 cases of zolpidem use and reported
adverse events in 1.1% of the cases. The most common
reported side effects were nausea, dizziness, malaise, hal-
lucination, nightmares, agitation, and headache [4]. Al-
though zolpidem appears to be well-tolerated in adults
and in the elderly, even when administered in accord-
ance with prescribing instructions [5], there are case re-
ports of abuse, dependence, withdrawal syndrome and
severe and various adverse effects [6-9]. However, in
the majority of these cases, the recommended dose of
zolpidem was exceeded and most patients had a his-
tory of substance abuse and/or a psychiatric disorders
[10]. In 1992, Ansseau et al. [11] reported the cases of
2 patients who developed visual hallucinations and
amnesia shortly after the intake of zolpidem. Iruela
et al. [12] reported a case of a patient presenting with
macropsia without amnesia. therefore, the number of
reports of neuropsychiatric reactions associated with* Correspondence: babaeianm@gmail.com
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should not be considered risk free, even at therapeutic
doses, and might produce transient cognitive and
behavioral impairments similar to those caused by
benzodiazepines [8,13-15].
Some authors [6,13,16-19] identify 4 factors associated
with increased risk of zolpidem-associated psychotic or
delirious reactions. One of them is using zolpidem doses
of 10 mg or higher.
We present a case of individual in whom using 20 mg
of zolpidem was associated with suicide ideation.Case presentation
A 27-year-old male, university student, unmarried, dor-
mitory resident with no known mood disorder or neuro-
psychological disease and abnormal sleep behaviors, had
self-referred to a medical toxicologist because of a new
experience with zolpidem abuse. He had no history of
health compromising or suicidal behaviors and was free
of neuropsychological drugs, except for PRN use of zol-
pidem 5 to maximum of 15 mg during the last year.
In May 2013 he declared that he had no dependence
to zolpidem. Despite his continuant use for weeks, he
strongly believed that he was not and would not be
addicted to zolpidem. He applied it as a sleeping drug at
first but after a while, he became interested in the pleas-
ant mental experiences of taking zolpidem even more
than its sleeping effect alone. The most important trig-
ger for his continuant abuse of zolpidem, as he said, was
his bad emotional status and pressure of thoughts which
got severe dramatically at nights. He described hisntral Ltd. This is an open access article distributed under the terms of the
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thing”. Gradually zolpidem could not make him sleep
anymore but instead resulted in spending his time doing
his favorite things such as listening to music, watching a
movie, web surfing or chatting up with friends.
The side effects of taking zolpidem, as reported by
him were nausea, vomiting, insomnia, nightmares, dizzi-
ness and hangover the next day, headache (very com-
mon), right side abdominal pain the next day, visual
hallucination, increased body temperature, talkativeness,
greasy hair, lack of control on his speech as telling per-
sonal secrets to others, feeling a bitter taste in saliva,
change of skin color and the smell of body sweat.
One night, after a rush of annoying thoughts, with a
great desire for zolpidem, he took two pills of zolpidem.
The following day he woke up with in sentiency at
8’o clock in the morning, thought a little to remember
the last night’s events, and memorized taking two pills of
zolpidem. After a few minutes he noticed the blister of
zolpidem by his bed side and saw that 6 of pills are
taken, while he was sure that it was a full blister and he
had taken just two of them last night. He tried his best
to remember exactly that what was happened last night
and the only result was suicidal thoughts by zolpidem;
After taking 20 mg of Zolpidem at first and beginning
the effect of the used zolpidem in a few minutes, he con-
sidered taking 4 other pills in order to suicide and did
not remember the afterwards.Conclusion
Zolpidem has a potential for either medical misuse when
the drug is continued long term without or against med-
ical advice, or recreational use when the drug is taken to
achieve a “high” [20]. Data from the “Centre for evaluation
and information on pharmacodependence” and the 53 lit-
erature case reports highlights significant dependence and
abuse potential of zolpidem [21].
There are some reports of suicidal attempts by zolpi-
dem, but to the best of our knowledge, this is the first
reported case of zolpidem-induced suicide attempt by
zolpidem.
In 1996 a 68-year-old female ingested at least 30 tab-
lets of 10 mg Ambien® was found dead at home. Toxico-
logical analyses revealed blood concentration of 4.1, 19.3
and 2.3 μg/ml of zolpidem, meprobamate and carisopro-
dol, respectively [22]. A study in 1999 on 8 postmortem
cases, reported 5 cases of deaths following zolpidem in-
toxication [23]. In 1999 Gock SB et al. report, the cause
of death for two cases was determined to be acute zolpi-
dem overdose, and manner of death was suicide [24].
It seems the patient attempted suicide when he was
under influence of the CNS effects of zolpidem. There-
fore it might be a high risk of attempting suicide whenpeople with no previous decision for suicide, take
zolpidem.
Because this case is based on one personal statement,
additional studies and investigations are needed to refute
or confirm this side effect, because zolpidem is a widely
used drug in the world and Iran.
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